CD4 and inflammatory bowel disease: These effects, combined with a lower proliferation of effector CD4+ T lymphocytes and the decrease in pro-inflammatory cytokine secretion could be a useful complement of the adequate drug treatment to shift the IBD gut toward a tolerogenic state.